Zura Bio Limited (NASDAQ:ZURA – Get Free Report) EVP Kiran Nistala bought 3,195 shares of the company’s stock in a transaction on Monday, April 22nd. The stock was purchased at an average cost of $3.13 per share, with a total value of $10,000.35. Following the completion of the transaction, the executive vice president now owns 3,195 shares in the company, valued at $10,000.35. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
Zura Bio Stock Down 4.9 %
ZURA stock opened at $3.31 on Thursday. The business’s 50-day moving average is $3.21 and its two-hundred day moving average is $4.04. Zura Bio Limited has a 1 year low of $2.00 and a 1 year high of $14.00.
Institutional Trading of Zura Bio
Several hedge funds have recently added to or reduced their stakes in ZURA. Armistice Capital LLC lifted its stake in Zura Bio by 66.3% in the third quarter. Armistice Capital LLC now owns 1,580,000 shares of the company’s stock worth $10,428,000 after acquiring an additional 630,000 shares during the last quarter. Silverarc Capital Management LLC raised its holdings in shares of Zura Bio by 152.5% in the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock valued at $2,667,000 after purchasing an additional 244,040 shares in the last quarter. Eisler Capital US LLC purchased a new stake in shares of Zura Bio during the 3rd quarter worth $660,000. Bank of New York Mellon Corp acquired a new position in shares of Zura Bio during the third quarter worth $224,000. Finally, Forefront Analytics LLC purchased a new position in Zura Bio in the third quarter valued at $95,000. Institutional investors and hedge funds own 61.14% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Stock Analysis on Zura Bio
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Further Reading
- Five stocks we like better than Zura Bio
- What is Put Option Volume?
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to Use the MarketBeat Excel Dividend Calculator
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.